Guangdong based drug bidding favors Anhui model and Shanghai model is in cold weather

Source: first financial daily, July 21, 2011, after various disadvantages of "Anhui model" in basic drug bidding were exposed, the pharmaceutical industry, especially brand pharmaceutical enterprises, had hoped that "Shanghai model" could be promoted in other appropriate provinces However, it is disappointing that neither Jiangsu Province nor Zhejiang Province has adopted the "Shanghai model" of "not only low price but also low price", while Guangdong Province, which launched the first bidding procurement of essential drugs in late June, is unlikely to adopt the "Shanghai model" "At present, Guangdong's bidding for essential drugs is still the" Anhui model "of" only low price theory ", and the possibility of referring to the" Shanghai model "is very small." Yesterday, Mr Zhao, who is in charge of the government affairs of a brand pharmaceutical enterprise in Guangdong, told reporters Only low price is to take the upper hand According to the implementation plan for centralized procurement of essential drugs by medical and health institutions in Guangdong Province, which started to be put on the Internet for comments yesterday, the bidding for essential drugs in Guangdong has indeed followed the "Anhui model": the "double envelope" evaluation method for technical and commercial bids, the three dosage forms of the first product, the first factory and the lowest price winner According to the "implementation plan", Guangdong's procurement of essential drugs this year includes 307 varieties in the national essential drugs catalogue and 244 local supplementary varieties The scope of use includes grass-roots hospitals below the county level and hospitals above the county level Mr Zhao told reporters that from the draft of "implementation plan", the core evaluation principle of "the lowest bidder wins the bid" will not change, which means that pharmaceutical enterprises will face price fight again in the bidding of Guangdong basic drugs Last year, after the "Anhui model" of "only low price theory" was implemented, there was a result of "bad money drives out good money" Brand pharmaceutical enterprises almost annihilated in Anhui, and most of the winning bidders were super low price varieties of small and medium-sized pharmaceutical enterprises In terms of actual procurement, the government of Anhui Province promised only 450 million yuan for 38 billion yuan of basic drugs The "Shanghai model" adopts the method of comprehensive evaluation, which increases the weight of quality The quality score accounts for 70%, and the price score only accounts for 30% It also divides the quality levels such as differential pricing From the results, brand pharmaceutical enterprises won the bid in the basic drug market for the first time, and Harbin Pharmaceutical Group, Shanghai Hehuang Pharmaceutical Co., Ltd and foreign drugs won the bid for the first time in China Our reporter noted that the bidding for basic drugs in Jiangsu and Zhejiang also followed the "Anhui model", and the relevant bid winning results have not yet been published However, brand pharmaceutical enterprises including Beijing Tongrentang, Guangyao Baiyunshan and some foreign enterprises have indicated to our reporter that there is little chance for enterprises to win the bidding at the current price Zhuo Yongqing, executive president of the pharmaceutical research and development industry committee of China Association of foreign funded enterprises, holds that "in the process of implementing the basic drug system, attention should be paid to the differences in disease spectrum, medical and health level, patients' needs and financial payment among regions For regions with better conditions, It can allow more and better medical and health products and services to be provided to the people, at least to ensure that the existing medical level does not decrease " In fact, foreign enterprises have made great concessions in the bidding of basic drugs in Shanghai, and the overall decline of the winning varieties is even close to 30% The Pharmaceutical Foreign Enterprise Association also hopes that if foreign enterprises can make similar concessions in the bidding of Guangdong basic drugs, their relevant varieties can enter the procurement of Guangdong basic drugs The head of Guangyao group said that as a brand pharmaceutical enterprise, it is confused at present According to the current domestic bidding trend of base drugs, the phenomenon of "price hanging upside down" of brand drugs has appeared many times in various provinces, many enterprises can only "reduce price for market" "Now brand pharmaceutical companies are doing multiple choice questions For the varieties that big hospitals can do, they will wait and even give up in the market of basic hospitals Some second-line varieties that are suitable for basic hospitals are willing to enter at a reduced price." Hangzhou a brand enterprise chemical medicine business department head told reporters The above practices in the field of implementing the basic drug system, although the overall price of basic drugs has declined, also have the results that run counter to the goal of the new medical reform: because the level of drug use in community hospitals in major cities across the country has declined, patients begin to return to large hospitals A director of a community hospital in Dongguan suggested that this phenomenon is common especially in the group of patients with chronic diseases Relevant policy design should increase the flexibility of drug use in the grass-roots hospitals, so as to ensure that patients can also obtain high-quality medical services in the grass-roots hospitals.